Dong-A ST 2Q Sales 154.1 Billion KRW... Operating Profit Up 103%

Dong-A ST (Dong-A ST) announced on the 27th that its provisional operating results for the second quarter of this year showed sales of 154.146 billion KRW and operating profit of 8.753 billion KRW. Compared to the same period last year, sales decreased by 3.8%, but operating profit increased by 103%.

Exterior view of Dong-A ST headquarters building
[Photo by Dong-A ST]

The company explained that "the prescription drug (ETC) sector and overseas business sector grew compared to the same period last year, but sales decreased due to the transfer of the diagnostic business operations to the affiliate Dong-A Chammed," calling it a temporary factor. Excluding the diagnostic business sector, sales grew by 4.2% year-on-year. They added, "Despite increased research and development (R&D) expenses, operating profit increased due to efficiency in selling and administrative expenses."

The ETC sector recorded sales of 102.5 billion KRW, a 5.0% increase compared to the same period last year, driven by increased sales of the growth hormone product 'Grotropin.' Grotropin led with sales of 20.9 billion KRW, followed by the functional dyspepsia treatment 'Motilitone' (7.8 billion KRW), the onychomycosis treatment 'Jublia' (7.3 billion KRW), and the diabetes treatment 'Suganon' (6.9 billion KRW).

The overseas business sector also posted sales of 40.9 billion KRW, a 1.5% increase year-on-year, supported by increased sales of Can Bacchus (24.5 billion KRW), the anemia treatment 'Darbepoetin Alfa BS' (3.8 billion KRW), and the tuberculosis treatments 'Croselin/Clopazimine' (2.7 billion KRW).

In terms of operating profit, despite R&D expenses increasing by 14% year-on-year to 22.7 billion KRW, the company showed a growth rate of 102.7% compared to the same period last year through increased product sales and efficiency in selling and administrative expenses.

This content was produced with the assistance of AI translation services.